



## Mirabegron

Updated: July 14, 2023.

## OVERVIEW

### Introduction

Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome. Mirabegron has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

### Background

Mirabegron (mir" a beg' ron) is a synthetic beta-3 adrenergic agonist which binds to receptors in the bladder that causes relaxation of the detrusor smooth muscle and results in an increase in the bladder capacity. Mirabegron has been evaluated as therapy of the overactive bladder syndrome, a condition marked by urgency, frequency, nocturia and incontinence that occurs most commonly in older women. Other therapies of overactive bladder include anticholinergics, but these are only partially effective and can have troublesome side effects, particularly in the elderly. In several short term clinical trials, mirabegron was found to increase voided volume and decrease episodes of incontinence and urinary frequency modestly. Mirabegron was approved for use in the United States in 2012 as treatment of overactive bladder with symptoms of urgency, incontinence, and frequency. In 2021, the indications were expanded to include treatment of children with neurogenic detrusor muscle instability using formulations of mirabegron granules. Mirabegron is available as 25 and 50 mg extended-release tablets under the brand name Myrbetriq. The typical dose in adults is 25 to 50 mg orally once daily. Mirabegron is also available as granules in solution of 8 mg/mL, and the typical dose in children is 48 or 80 mg daily. Side effects are not common, but can include nausea, diarrhea, constipation, dizziness, tachycardia, palpitations, hypertension, and headache. Rare, but potentially severe side effects include hypertension, urinary retention, and hypersensitivity reactions, angioedema, and rash.

### Hepatotoxicity

In preregistration clinical trials, serum aminotransferase elevations were uncommon and mild in patients treated with mirabegron and rates of serum enzyme elevations were similar to those with placebo treatment. Among several thousands of patients treated, there were no episodes of clinically apparent liver injury. Since its approval and more widescale use, there have not been any published reports of hepatotoxicity attributed to mirabegron. However, the product label for mirabegron mentions occasional elevations in ALT and AST associated with treatment as well as a case of Stevens Johnson syndrome with aminotransferase elevations. Thus, mirabegron may cause hepatic injury as a part of a generalized hypersensitivity reactions.

Likelihood score: E\* (unproven but suspected rare cause of clinically apparent liver injury).

## Mechanism of Injury

The possible cause of liver injury due to mirabegron is not known but might result from a generalized hypersensitivity reaction. Mirabegron is metabolized in part by CYP 2D6, but drug-drug interactions with agents that inhibit or induce this enzyme are uncommon.

Drug Class: Urologic Agents, Overactive Bladder Syndrome Agents

Other Drugs in the Subclass, Overactive Bladder Syndrome Agents: [Darifenacin](#), [Fesoterodine](#), [Flavoxate](#), [Hyoscyamine](#), [Oxybutynin](#), [Solifenacin](#), [Tolterodine](#), [Trospium](#), [Vibegron](#)

## PRODUCT INFORMATION

### REPRESENTATIVE TRADE NAMES

Mirabegron – Myrbetriq®


### DRUG CLASS

Urologic Agents

### COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

## CHEMICAL FORMULA AND STRUCTURE

DRUG	CAS REGISTRY NO.	MOLECULAR FORMULA	STRUCTURE
Mirabegron	223673-61-8	C <sub>21</sub> -H <sub>24</sub> -N <sub>4</sub> -O <sub>2</sub> -S	 <p>The chemical structure of Mirabegron is shown. It consists of a benzophenone moiety (a benzene ring attached to a carbonyl group, which is further attached to a methylene group) connected via a secondary amine to another methylene group. This second methylene group is attached to a para-substituted benzene ring. This benzene ring is further connected via a secondary amine to a carbonyl group, which is attached to a methylene group. This methylene group is attached to a 1,2,4-triazole ring system.</p>

## ANNOTATED BIBLIOGRAPHY

References updated: 14 July 2023

Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.

*(Expert review of hepatotoxicity published in 1999 before the availability of mirabegron).*

Westfall TC, Macarthur H, Westfall DP. Adrenergic agonists and antagonists. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 191-223.

*(Textbook of pharmacology and therapeutics).*

Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the  $\beta_3$ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. *Urology* 2013; 82: 313-20. PubMed PMID: 23769122.

*(Among 1306 patients with overactive bladder syndrome treated with mirabegron [25 or 50 mg] or placebo daily for 12 weeks, episodes of incontinence and numbers of micturitions per day decreased with mirabegron, and side effects were mild and "the overall incidence of hepatic treatment emergent adverse events was similar across treatment groups; most were mild or moderate").*

Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambroner J, Angulo JC, Blauwet MB, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. *Int J Clin Pract* 2013; 67: 619-32. PubMed PMID: 23692526.

*(In a pooled analysis of 3 placebo controlled trials, 3542 patients with overactive bladder syndrome were treated with mirabegron [25, 50 or 100 mg] or placebo daily for 12 weeks; adverse event rates were no different with mirabegron than placebo; no mention of ALT elevations or hepatotoxicity).*

Khullar V, Amarenco G, Angulo JC, Cambroner J, Høye K, Milsom I, Radziszewski P, et al. Efficacy and tolerability of mirabegron, a  $\beta(3)$ -adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. *Eur Urol* 2013; 63: 283-95. PubMed PMID: 23182126.

*(Among 1978 patients with overactive bladder syndrome treated with once daily mirabegron [50 or 100 mg], tolterodine [4 mg] or placebo for 12 weeks, adverse event rates were similar among groups, and "changes in...serum chemistry parameters...were small and consistent across treatment groups").*

Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, et al.; Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. *Int Urogynecol J* 2013; 24: 1447-58. PubMed PMID: 23471546.

*(Among 928 adults with overactive bladder treated with mirabegron [25, 50, 100 or 200 mg daily], there was a dose related reduction in frequency of micturition, and side effects included increase in pulse rate at the high doses, but "there were no clinically relevant changes in laboratory parameters").*

Otsuki H, Kosaka T, Nakamura K, Mishima J, Kuwahara Y, Tsukamoto T.  $\beta_3$ -Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. *Int Urol Nephrol* 2013; 45: 53-60. PubMed PMID: 23212147.

*(Among 97 patients with overactive bladder treated with mirabegron [50 mg daily] for 8 weeks, 74% had improvement in symptoms and there was no liver related adverse events).*

Mirabegron (Myrbetriq) for overactive bladder. *Med Lett Drugs Ther* 2013; 55 (1410): 13-5.

*(Concise review of mechanism of action, clinical efficacy, safety and costs of mirabegron and other treatments for overactive bladder syndrome; mentions side effects of nausea, diarrhea, constipation, dizziness, tachycardia and headache, but not ALT elevations or hepatotoxicity).*

Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 2013; 144: 1419-25. PubMed PMID: 23419359.

*(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to mirabegron).*

Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S, Milsom I, Auerbach S, et al. Safety and tolerability of the  $\beta_3$ -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. *Int J Clin Pract* 2014; 68: 972-85. PubMed PMID: 24703195.

*(Pooled analysis of safety of mirabegron [25, 50 and 100 mg daily] from three 12-week and one 1-year studies reported side effects of hypertension, headache, back pain, drug mouth and constipation low and similar to rates in placebo recipients; elevations in ALT above 3 times ULN occurred in 1.5% on mirabegron, 1.4% on placebo and 2.0% on tolterodine, and no patient had concurrent elevation in bilirubin or clinically apparent liver injury).*

Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. *Ann Hepatol* 2014; 13: 231-9. PubMed PMID: 24552865.

*(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, but none were attributed to mirabegron).*

Chalasanani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. *Gastroenterology* 2015; 148: 1340-1352.e7. PubMed PMID: 25754159.

*(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to mirabegron or other agents for overactive bladder syndrome).*

Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronerio J, Halaska M, Coppell A, et al.; BEYOND study group. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. *Ther Adv Urol* 2015; 7: 167-79. PubMed PMID: 26445596.

*(Among 1887 patients with overactive bladder treated with mirabegron or solifenacin for 12 weeks, decreases in micturition rates were similar with the two drugs [3.0 and 3.1 per day] as were rates of adverse events; no mention of ALT levels or hepatotoxicity).*

Thiagamoorthy G, Cardozo L, Srikrishna S. Drug therapy for an overactive bladder. *Womens Health (Lond)* 2015; 11: 445-8. PubMed PMID: 26238677.

*(Overactive bladder is defined as urinary urgency, usually with frequency and nocturia with or without incontinence in the absence of infection or other known cause; medical therapy being use of anticholinergics or beta-3 agonists such as mirabegron which has fewer side effects than typical anticholinergics).*

Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. *Ther Adv Drug Saf* 2016; 7: 204-216. PubMed PMID: 27695622.

*(Review of the 3 phase III trials of mirabegron for overactive bladder syndrome; no discussion of liver related adverse events).*

Kallner HK, Christensson AA, Elmér C, Flam B, Altman D. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study. *Eur J Obstet Gynecol Reprod Biol* 2016; 203: 167-72. PubMed PMID: 27318184.

*(Among 221 women with overactive bladder syndrome treated in clinical practice at a single medical center, 16 patients stopped therapy because of side effects including palpitations, chest pain, dry mouth, diarrhea, headache, fatigue, blurred vision and edema; no mention of liver related adverse events).*

Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. *Eur Urol* 2016; 70: 9-13. PubMed PMID: 26876327.

*(Among 58 children with overactive bladder treated with mirabegron for a median of 11 months, bladder capacity increased and incontinence decreased, while most children tolerated therapy with no change in pulse or blood pressure and infrequent symptoms of nausea, personality change and nasal stuffiness; no mention of ALT elevations or hepatotoxicity).*

Sager C, Sanmartino M, Burek C, Gomez YR, Vazquez Patiño M, Weller S, Ruiz J, et al. Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. *J Pediatr Urol*. 2020;16:655.e1-655.e6.

*(Among 37 children with neurogenic bladder dysfunction treated with mirabegron [25 mg daily], bladder capacity increased, while therapy was well tolerated, and ALT and AST values did not change).*

Baka-Ostrowska M, Bolong DT, Persu C, Tøndel C, Steup A, Lademacher C, Martin N. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study. *Neurourol Urodyn*. 2021;40:1490-1499. PubMed PMID: 34058027.

*(Among 86 children ages 3 to 18 years treated with mirabegron [25 to 50 mg daily] for up to 24 weeks, bladder capacity was increased, while adverse events arose in 59% of patients but few were considered related with therapy; no mention of ALT elevations but one patient had transient, mild creatine kinase and AST elevations).*

Soliman MG, El-Abd S, El-Gamal OM, Raheem AA, Abou-Ramadan AR, El-Abd AS. Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial. *Urol Int*. 2021;105:1011-1017. PubMed PMID: 34010843.

*(Among 190 children ages 5 to 14 years with overactive bladder syndrome treated with mirabegron [50 mg], solifenacin [5 mg], or placebo once daily for 3 months, clinical responses were higher with medical therapy [88% and 90% vs 56%], while adverse events included dry mouth [3% and 10% vs 0%], constipation [3% and 11% vs 1%]; no mention of ALT elevations or hepatotoxicity).*

Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H. Comparison of mirabegron and vibegron in women with treatment-naïve overactive bladder: A randomized controlled study. *Urology*. 2023;175:67-73. PubMed PMID: 36822245.

*(Among 199 adult women with overactive bladder syndrome treated with 50 mg of either mirabegron or vibegron daily for 12 weeks, response rates were similar in both groups as were overall rates of adverse events [17.5% vs 15.7%], discontinuations [6.2% vs 6.8%], constipation [10.3% vs 11.8%], dry mouth [both 1%], and rash [2% vs 1%]; no mention of ALT elevations or hepatotoxicity).*

Drugs for overactive bladder. *Med Lett Drugs Ther*. 2023;65:41-45. PubMed PMID: 36897601.

*(Concise review of drugs approved for therapy of overactive bladder in the US including anticholinergic agents [darifenacin, fesoterodine, oxbutynin, solifenacin, tolterodine and trospium] and beta-3 adrenergic receptor agonists [mirabegron and vibegron] including clinical efficacy, safety, and costs; no mention of ALT elevations or hepatotoxicity of any of the agent discussed).*